3) Bharat iierrras ... The Key, to Eradicate Polio SR eR CUCU R eRe Ce ACE) aS org Advantages of bivalent Oral Polio (bOPV) VaccineStudy Results: Immunogenicity & Safety Proven thro’ Bharat Biotech's Pivotal Phase Ill Clinical Trials on BIOPOLIO B1/3* Geometric Mean Titres (GMT) ies cules Pal m= bOPV we] torw I Antibody titres 150 100 so ° : : ee FEF SF Reith Day30. Day 44 ‘Seroconversion 100 . = sory gw] = or 2 60 2 & eR 20- ° se e Dayo Day aa The most common adverse events reported BS were fever, cough, cold & vorniting ‘Adverse Events when treated symptomatically. 10- Allevents were resolved within 24-48 hours. = tory E cf mtr 2 ‘ é fe $2 BIOPOLIO B1/3 - WHO Prequalified Vaccine More than 2 billion doses sold Worldwide Farmar pas fal nema wrereo@tartoe.om @ Bharat Biotech Leool novation, Gene ey Hyesbad -50 078. TS. ida, oar. eom - Clinically Proven Immunogenicity & Safety No shedding of Vaccine Virus LUMEMET A ne tp of sal oes hassle ree administrationBiopolio B1-3 Product Literature Printing Specifications: single page Size : W-8"x H-11.4”inches Print : Multi colour 2 pages front & back Card : Foreign Art Card GSM :280 GSM Finishing : Matt + Texture and Raised Glass UV Qty.: 10000 no's Pack :Each 100 pack